MX2012003514A - Metodos para tratamiento de inflamaciones. - Google Patents
Metodos para tratamiento de inflamaciones.Info
- Publication number
- MX2012003514A MX2012003514A MX2012003514A MX2012003514A MX2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A MX 2012003514 A MX2012003514 A MX 2012003514A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- mif
- treating inflammation
- cxcr2
- cxcr4
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 abstract 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 abstract 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 abstract 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24521409P | 2009-09-23 | 2009-09-23 | |
| US31903910P | 2010-03-30 | 2010-03-30 | |
| PCT/US2010/050047 WO2011038149A2 (en) | 2009-09-23 | 2010-09-23 | Methods of treating inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012003514A true MX2012003514A (es) | 2012-04-19 |
Family
ID=43796491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012003514A MX2012003514A (es) | 2009-09-23 | 2010-09-23 | Metodos para tratamiento de inflamaciones. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2480579A4 (enExample) |
| KR (1) | KR20120105429A (enExample) |
| CN (1) | CN102725311A (enExample) |
| AU (1) | AU2010298249A1 (enExample) |
| BR (1) | BR112012006468A2 (enExample) |
| CA (1) | CA2773978A1 (enExample) |
| IN (1) | IN2012DN02423A (enExample) |
| MX (1) | MX2012003514A (enExample) |
| WO (1) | WO2011038149A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| US9328174B2 (en) * | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| CA2873808C (en) * | 2012-05-17 | 2021-04-27 | Cyon Therapeutics Inc. | Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors |
| TW201605886A (zh) * | 2013-11-14 | 2016-02-16 | 巴克斯特保健公司 | 作爲治療標靶的ｍｉｆ |
| MX386771B (es) | 2016-03-11 | 2025-03-19 | Ardea Biosciences Inc | Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales. |
| AU2019282132A1 (en) | 2018-06-05 | 2020-12-17 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
| CA3123290A1 (en) * | 2018-12-26 | 2020-07-02 | Colgate-Palmolive Company | Biomarkers of neutrophil deregulation as diagnostic for gingivitis |
| EP4117704A4 (en) * | 2020-03-11 | 2024-04-10 | BioLineRx Ltd. | Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections |
| WO2021219495A1 (en) * | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
| CN112656934A (zh) * | 2021-01-22 | 2021-04-16 | 深圳市图微安创科技开发有限公司 | 多肽at03在治疗原发性胆汁性胆管炎药物中的应用 |
| EP4378319A1 (en) * | 2022-12-01 | 2024-06-05 | Bioiberica, S.A.U. | Composition comprising bioactive peptides |
| CN119318647A (zh) * | 2024-08-14 | 2025-01-17 | 南方医科大学 | Sb225002在制备治疗心肌梗死的药物中的应用、治疗心肌梗死的组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
| WO2003072753A2 (en) * | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
| WO2003074567A2 (en) * | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| WO2005065328A2 (en) * | 2003-12-30 | 2005-07-21 | The United States Of America, As Represented By The Department Of Veterans Affairs | Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EA201001529A1 (ru) * | 2008-03-20 | 2011-06-30 | Каролус Терапьютикс, Инк. | Способ и композиция для лечения mif-опосредованных расстройств |
| WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
-
2010
- 2010-09-23 BR BR112012006468A patent/BR112012006468A2/pt not_active IP Right Cessation
- 2010-09-23 CN CN2010800526286A patent/CN102725311A/zh active Pending
- 2010-09-23 IN IN2423DEN2012 patent/IN2012DN02423A/en unknown
- 2010-09-23 CA CA2773978A patent/CA2773978A1/en not_active Abandoned
- 2010-09-23 AU AU2010298249A patent/AU2010298249A1/en not_active Abandoned
- 2010-09-23 KR KR1020127010455A patent/KR20120105429A/ko not_active Withdrawn
- 2010-09-23 WO PCT/US2010/050047 patent/WO2011038149A2/en not_active Ceased
- 2010-09-23 EP EP10819481.2A patent/EP2480579A4/en not_active Withdrawn
- 2010-09-23 MX MX2012003514A patent/MX2012003514A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN02423A (enExample) | 2015-08-21 |
| KR20120105429A (ko) | 2012-09-25 |
| WO2011038149A2 (en) | 2011-03-31 |
| WO2011038149A3 (en) | 2011-10-27 |
| AU2010298249A1 (en) | 2012-04-19 |
| BR112012006468A2 (pt) | 2016-08-09 |
| CA2773978A1 (en) | 2011-03-31 |
| EP2480579A2 (en) | 2012-08-01 |
| EP2480579A4 (en) | 2013-07-31 |
| CN102725311A (zh) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012003514A (es) | Metodos para tratamiento de inflamaciones. | |
| WO2009117710A3 (en) | Methods of treating inflammation | |
| MX2020007226A (es) | Composiciones de corticosteroides administradas oralmente. | |
| AU2008232453A8 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| MX2010009724A (es) | Procedimientos de tratamiento del dolor inflamatorio-. | |
| PL1986669T3 (pl) | Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia | |
| PH12014500075A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| TW200738262A (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
| WO2010062581A3 (en) | A botanical composition for enhanced skin repair and uses thereof | |
| WO2009080800A3 (en) | Method for decreasing abdominal girth by administering a bifidobacterium bacteria | |
| IN2014DN08385A (enExample) | ||
| WO2009016488A3 (en) | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods | |
| GB201017889D0 (en) | A polymeric nanoparticle | |
| WO2011044523A3 (en) | Compositions and methods for treating obesity | |
| SG179069A1 (en) | Cancer stem cell-targeted and drug resistant cancer therapy | |
| MY161853A (en) | Pharmaceutical composition and method for treating hypertension | |
| EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
| WO2011041325A3 (en) | Methods and compositions for the treatment of viral disorders | |
| WO2011116245A3 (en) | Methods of treating inflammation | |
| AU2010298020A8 (en) | Combination | |
| WO2008073317A3 (en) | Cytarabine for treatment of glioma | |
| TN2011000206A1 (en) | Compositions and methods of use soluble thrombomodulin variants | |
| UA83743C2 (ru) | Способ профилактики и коррекции сниженных функциональных возможностей центральной нервной системы | |
| UA38340U (ru) | Способ лечения женщин с патологическим прелиминарным периодом |